Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Axitinib in Neoadjuvant Non-ccRCC
NCT04385654Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in non-clear cell renal cell carcinoma (nccRCC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Major Pathologic Response at 6 weeks, Pathologic Complete Response at 6 weeks and 1 more. Status: unknown.
02
Drugs
toripalimab
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT04385654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385654.